(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 August 2003 (14.08.2003)

PCT

(10) International Publication Number
WO 03/066589 A1

(51) International Patent Classification[7]: C07D 211/58, 401/04, 405/12, A61K 31/451, 31/4525, 31/5377, 31/497, A61P 25/22, 25/24

(21) International Application Number: PCT/GB03/00499

(22) International Filing Date: 5 February 2003 (05.02.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0203021.1	8 February 2002 (08.02.2002)	GB
0203019.5	8 February 2002 (08.02.2002)	GB

(71) Applicant *(for all designated States except US)*: **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ALVARO, Giuseppe** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **PAIO, Alfredo** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **PONTIROLI, Alessandro** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **SPADA, Simone** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT). **TRANQUILLINI, Maria, Elvira** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT).

(74) Agent: **THOMPSON, Clive, Beresford**; CN925.1, 980 Great West Road, Brentford, Middlesex TW7 9GS (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: PIPERIDYLCARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF TACHYKININ-MEDIATED DISEASES



(I)

(57) Abstract: The present invention relates to piperidine derivatives of formula (I) wherein R represents halogen or C_{1-4}alkyl; R_1 represents hydrogen or C_{1-4} alkyl; R_2 represents hydrogen , C_{1-4} alkyl or R_2 together with R_3 represents C_{3-7} cycloalkyl; R_3 represents hydrogen, C_{1-4} alkyl, C_{3-7} cycloalkyl or C_{3-6} alkenyl; or R_1 and R_3 together with nitrogen and carbon atom to which they are attached respectively represent a 5 to 6 membered heterocyclic group; R_4 represents trifluoromethyl, C_{1-4} alkyl, C_{1-4} alkoxy, trifluoromethoxy or halogen; R is hydrogen and R is NR_7R_8 or R_5 is NR_8R_9 and R_6 is hydrogen; R_7 represents hydrogen or C_{1-4} alkyl or R_7 and R_8 together with nitrogen to which they are attached are a saturated 5 to 7 membered heterocyclic group containing oxygen; R_8 represents hydrogen, phenyl, C_{3-7}cycloalkyl, (CH2)pC(O)$NR_{10}R_{11}$, a saturated 5 to 7 membered heterocyclic group containing 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen and optionally substituted by C_{1-4} alkyl, $S(O)_2C_{1-4}$ alkyl or C(O) C_{1-4} alkyl, a 5 membered heteroaryl group containing 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen and optionally substituted by C_{1-4} alkyl $S(O)_2C_{1-4}$alkyl or C(O) C_{1-4} alkyl or R_8 represents a 6 membered heteroaryl group containing 1 to 3 nitrogen atoms and optionally substituted by C_{1-4}alkyl, $S(O)_2C_{1-4}$ alkyl or C(O) C_{1-4}alkyl; or R_8 is a C_{1-6} alkyl group optionally substituted by one or two groups selected from fluorine, phenyl(optionally substituted by C_{1-4} alkyl, C(O) C_{1-4} alkyl or halogen), =O, C_{3-7}cycloalkyl, hydroxy, amino, dimethylamino, aminocarbonyl, C_{1-4}alkoxy or trifluoromethyl; R_9 is hydrogen, C_{1-4} alkyl or R_9 and R_8 together with nitrogen to which they are attached are a 5 to 7 membered heterocyclic group optionally containing another heroatom selected from oxygen, sulphur and nitrogen and optionally substituted by one or two groups selected from C_{1-4} alkyl, =O, $S(O)_2C_{1-4}$ alkyl, C(O) C_{3-7}cycloalkyl or C(O) C_{1-4} alkyl; R_{10} and R_{11} are independently hydrogen or C_{1-4} alkyl group; X represents a nitrogen atom and Y is CH or X represents CH and Y is nitrogen;m is zero or an integer from 1 to 3; n is an integer from 1 to 3; p is zero, 1 or 2; and pharmaceutically acceptable salts and solvates thereof; the process for their preparation and their use in the treatment of conditions mediated by tachykinins.

WO 03/066589 A1